

Shun Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1836959/publications.pdf>

Version: 2024-02-01

246
papers

19,494
citations

66234

42
h-index

12910

131
g-index

256
all docs

256
docs citations

256
times ranked

14530
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 735-742. | 5.1 | 3,758 |
| 2 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830. | 6.3 | 2,347 |
| 3 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222. | 5.1 | 1,740 |
| 4 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151. | 5.1 | 1,369 |
| 5 | Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1711-1723. | 13.9 | 1,042 |
| 6 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589. | 5.1 | 950 |
| 7 | Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1973-1985. | 13.9 | 871 |
| 8 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211. | 5.1 | 773 |
| 9 | BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2197-2204. | 0.8 | 323 |
| 10 | The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1378-1389. | 0.5 | 310 |
| 11 | Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875. | 0.5 | 260 |
| 12 | Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1405-1411. | 0.8 | 230 |
| 13 | IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740. | 0.5 | 205 |
| 14 | Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 709. | 3.4 | 185 |
| 15 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overlode 5.2 169 8. 1132-1143. | | |
| 16 | Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548. | 0.5 | 146 |
| 17 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1512-1522. | 0.5 | 127 |
| 18 | FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. <i>Oncogene</i> , 2018, 37, 5340-5354. | 2.6 | 123 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947. | 0.5 | 119 |
| 20 | Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9501-9501. | 0.8 | 119 |
| 21 | Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1154-1164. | 5.2 | 107 |
| 22 | Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8503-8503. | 0.8 | 99 |
| 23 | Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. <i>Cancer Cell</i> , 2021, 39, 1279-1291.e3. | 7.7 | 99 |
| 24 | Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 423-433. | 0.5 | 89 |
| 25 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918. | 0.5 | 85 |
| 26 | Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1119-1136. | 0.5 | 82 |
| 27 | Exosomal miR-499a-5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma. <i>Experimental Cell Research</i> , 2019, 379, 203-213. | 1.2 | 79 |
| 28 | EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017, 116, 175-185. | 2.9 | 76 |
| 29 | AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. <i>Journal of Clinical Oncology</i> , 2022, 40, 3162-3171. | 0.8 | 76 |
| 30 | NF- κ B-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. <i>Oncotarget</i> , 2015, 6, 8244-8254. | 0.8 | 73 |
| 31 | Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 411-422. | 0.5 | 70 |
| 32 | High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2544-2549. | 3.3 | 67 |
| 33 | Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 987-995. | 0.5 | 67 |
| 34 | Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. <i>Translational Lung Cancer Research</i> , 2020, 9, 269-279. | 1.3 | 64 |
| 35 | Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. <i>Cancer Communications</i> , 2018, 38, 1-12. | 3.7 | 57 |
| 36 | The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. <i>Cancer Letters</i> , 2018, 423, 36-46. | 3.2 | 52 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo. <i>Cellular Signalling</i> , 2015, 27, 1208-1213. | 1.7 | 51 |
| 38 | FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 72. | 3.5 | 50 |
| 39 | Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). <i>Journal of Clinical Oncology</i> , 2020, 38, 9519-9519. | 0.8 | 50 |
| 40 | The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. <i>FEBS Letters</i> , 2014, 588, 3000-3007. | 1.3 | 47 |
| 41 | TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5173-5180. | 3.2 | 47 |
| 42 | Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. <i>Oncotarget</i> , 2017, 8, 9996-10006. | 0.8 | 47 |
| 43 | SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). <i>Journal of Clinical Oncology</i> , 2022, 40, 1BA8507-1BA8507. | 0.8 | 46 |
| 44 | Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-Small-Cell Lung Cancer: LAURA Trial in Progress. <i>Clinical Lung Cancer</i> , 2021, 22, 371-375. | 1.1 | 44 |
| 45 | LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. <i>Journal of Clinical Oncology</i> , 2013, 31, 8016-8016. | 0.8 | 44 |
| 46 | MARIPOSA: phase 3 study of first-line amivantamab + azaertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 639-647. | 1.1 | 44 |
| 47 | FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. <i>Oncotarget</i> , 2016, 7, 15118-15134. | 0.8 | 42 |
| 48 | Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2015, 76, 134-140. | 2.5 | 41 |
| 49 | Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. <i>Oncogenesis</i> , 2019, 8, 50. | 2.1 | 41 |
| 50 | Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 19-24. | 0.9 | 41 |
| 51 | Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. <i>Lung Cancer</i> , 2018, 126, 1-8. | 0.9 | 40 |
| 52 | EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 732-736. | 0.5 | 40 |
| 53 | Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14. | 0.9 | 40 |
| 54 | Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2012, 30, 7520-7520. | 0.8 | 40 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 206-211. | 0.5 | 39 |
| 56 | Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. <i>Oncotarget</i> , 2016, 7, 18394-18402. | 0.8 | 38 |
| 57 | Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness. <i>EBioMedicine</i> , 2019, 41, 236-243. | 2.7 | 38 |
| 58 | Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics. <i>Nature Communications</i> , 2019, 10, 3856. | 5.8 | 37 |
| 59 | Tumor invasiveness defined by IASLC/ATS/ERS classification of ground-glass nodules can be predicted by quantitative CT parameters. <i>Journal of Thoracic Disease</i> , 2017, 9, 1190-1200. | 0.6 | 36 |
| 60 | A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020, 10, 578756. | 1.3 | 36 |
| 61 | Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 3.3 | 36 |
| 62 | SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation. <i>Oncotarget</i> , 2016, 7, 18927-18939. | 0.8 | 33 |
| 63 | Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPAR α /PTEN/mTOR signaling pathway. <i>BMC Cancer</i> , 2018, 18, 407. | 1.1 | 33 |
| 64 | Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met α overexpressing (OE) advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9016-9016. | 0.8 | 33 |
| 65 | Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 401-407. | 0.9 | 31 |
| 66 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579. | 1.2 | 31 |
| 67 | FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response. <i>Nucleic Acids Research</i> , 2014, 42, 11560-11569. | 6.5 | 30 |
| 68 | Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 176-189. | 0.5 | 29 |
| 69 | FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer. <i>Cell Adhesion and Migration</i> , 2020, 14, 82-95. | 1.1 | 29 |
| 70 | Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 989-999. | 1.3 | 28 |
| 71 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131. | 0.9 | 26 |
| 72 | The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. <i>Translational Lung Cancer Research</i> , 2020, 9, 1770-1784. | 1.3 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414. | 0.5 | 26 |
| 74 | Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. <i>BMC Medicine</i> , 2022, 20, 42. | 2.3 | 26 |
| 75 | Prognostic Significance of the Extent of Lymph Node Involvement in Stage II-N1 Non-small Cell Lung Cancer. <i>Chest</i> , 2013, 144, 1253-1260. | 0.4 | 25 |
| 76 | Evaluation of the VeriStrat [®] serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017, 109, 101-108. | 0.9 | 25 |
| 77 | The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. <i>Oncotargets and Therapy</i> , 2014, 7, 387. | 1.0 | 24 |
| 78 | Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, e157-e159. | 0.5 | 24 |
| 79 | First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 3310-3318. | 1.3 | 24 |
| 80 | Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9013-9013. | 0.8 | 24 |
| 81 | Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8453-61. | 0.5 | 24 |
| 82 | Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. <i>Clinical Cancer Research</i> , 2022, 28, 461-467. | 3.2 | 24 |
| 83 | Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. <i>Oncology Reports</i> , 2008, 20, 581-7. | 1.2 | 24 |
| 84 | Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients. <i>Journal of Hematology and Oncology</i> , 2022, 15, 62. | 6.9 | 24 |
| 85 | Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1207-1217. | 0.8 | 23 |
| 86 | Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. <i>PLoS ONE</i> , 2018, 13, e0205827. | 1.1 | 23 |
| 87 | Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 839-847. | 0.8 | 23 |
| 88 | Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104. <i>Oncogene</i> , 2020, 39, 3507-3521. | 2.6 | 23 |
| 89 | A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9025-9025. | 0.8 | 23 |
| 90 | Acetylcholine receptor pathway in lung cancer: New twists to an old story. <i>World Journal of Clinical Oncology</i> , 2014, 5, 667. | 0.9 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer. <i>Biochimie</i> , 2015, 112, 111-120. | 1.3 | 22 |
| 92 | Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2016, 17, 985-994. | 0.6 | 22 |
| 93 | Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, S21-S30. | 1.9 | 22 |
| 94 | Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8575-8587. | 1.0 | 21 |
| 95 | Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma. <i>Translational Oncology</i> , 2021, 14, 101148. | 1.7 | 21 |
| 96 | Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib LUX-Lung 5 (LL5). <i>Journal of Clinical Oncology</i> , 2014, 32, 8019-8019. | 0.8 | 21 |
| 97 | Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). <i>Patient</i> , 2018, 11, 131-141. | 1.1 | 20 |
| 98 | Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. <i>Science China Life Sciences</i> , 2020, 63, 1499-1514. | 2.3 | 20 |
| 99 | Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). <i>Clinical Cancer Research</i> , 2021, 27, 704-712. | 3.2 | 20 |
| 100 | Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. <i>Lung Cancer</i> , 2018, 123, 83-86. | 0.9 | 19 |
| 101 | Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7323-7328. | 1.0 | 19 |
| 102 | Clinic application of tissue engineered bronchus for lung cancer treatment. <i>Journal of Thoracic Disease</i> , 2017, 9, 22-29. | 0.6 | 18 |
| 103 | PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction. <i>International Immunopharmacology</i> , 2019, 66, 127-138. | 1.7 | 18 |
| 104 | Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , 2021, 154, 176-185. | 0.9 | 18 |
| 105 | Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 759217. | 2.2 | 18 |
| 106 | A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. <i>International Journal of Nanomedicine</i> , 2016, 11, 2119. | 3.3 | 17 |
| 107 | Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 5003-5014. | 3.2 | 16 |
| 108 | Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189. | 1.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 678753. | 1.6 | 16 |
| 110 | Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <i>NTRK</i> fusion-positive (<i>NTRK</i> -fp) solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3099-3099. | 0.8 | 16 |
| 111 | Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. <i>Journal of Thoracic Oncology</i> , 2022, 17, 816-826. | 0.5 | 15 |
| 112 | Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases. <i>SpringerPlus</i> , 2016, 5, 894. | 1.2 | 14 |
| 113 | Xenograft tumors derived from malignant pleural effusion of the patients with non-small cell lung cancer as models to explore drug resistance. <i>Cancer Communications</i> , 2018, 38, 1-12. | 3.7 | 14 |
| 114 | MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A. <i>International Journal of Immunopathology and Pharmacology</i> , 2019, 33, 205873841984148. | 1.0 | 14 |
| 115 | Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9022-9022. | 0.8 | 14 |
| 116 | Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors. <i>Medicinal Chemistry</i> , 2016, 12, 613-620. | 0.7 | 14 |
| 117 | Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 909. | 0.3 | 14 |
| 118 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296. | 3.2 | 14 |
| 119 | Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB-III A) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA8511-LBA8511. | 0.8 | 14 |
| 120 | Transforming growth factor- β 1-induced epithelial to mesenchymal transition increases mitochondrial content in the A549 non-small cell lung cancer cell line. <i>Molecular Medicine Reports</i> , 2015, 11, 417-421. | 1.1 | 13 |
| 121 | Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. <i>Lung</i> , 2015, 193, 805-814. | 1.4 | 13 |
| 122 | Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2308-2314. | 0.5 | 13 |
| 123 | Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung – A Multicenter, Open-label, Randomized, Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1743-1749. | 0.5 | 13 |
| 124 | Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing. <i>International Journal of Medical Sciences</i> , 2021, 18, 1510-1518. | 1.1 | 13 |
| 125 | The <i>in cis</i> compound <i>EGFR</i> mutations in Chinese advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2019, 20, 1097-1104. | 1.5 | 13 |
| 126 | A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017, 8, 41474-41486. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Inhibition of the growth of non-small cell lung cancer by miRNA-1271. American Journal of Translational Research (discontinued), 2015, 7, 1917-24. | 0.0 | 13 |
| 128 | Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. Clinical and Experimental Immunology, 2022, 208, 316-322. | 1.1 | 13 |
| 129 | Everolimus and zoledronic acid—a potential synergistic treatment for lung adenocarcinoma bone metastasis. Acta Biochimica Et Biophysica Sinica, 2014, 46, 792-801. | 0.9 | 12 |
| 130 | A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer â€œ The FALUCA study. Lung Cancer, 2020, 146, 252-262. | 0.9 | 12 |
| 131 | Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component. Frontiers in Oncology, 2021, 11, 652193. | 1.3 | 12 |
| 132 | Propensity score matched analysis for the role of surgery in stage â…¸ small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital. Lung Cancer, 2021, 162, 54-60. | 0.9 | 12 |
| 133 | First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic nonâ€œsmall cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.. Journal of Clinical Oncology, 2022, 40, LBA9026-LBA9026. | 0.8 | 12 |
| 134 | Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma. Cancer Medicine, 2016, 5, 2323-2331. | 1.3 | 11 |
| 135 | Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Nonâ€œSmall-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, e103-e112. | 1.1 | 11 |
| 136 | Î²Klotho is identified as a target for theranostics in non-small cell lung cancer. Theranostics, 2019, 9, 7474-7489. | 4.6 | 11 |
| 137 | Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma. Journal of Thoracic Disease, 2019, 11, 4258-4270. | 0.6 | 11 |
| 138 | MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1. Cancer Cell International, 2020, 20, 413. | 1.8 | 11 |
| 139 | Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Future Oncology, 2021, 17, 4237-4247. | 1.1 | 11 |
| 140 | First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. Journal of Clinical Oncology, 2016, 34, 9046-9046. | 0.8 | 11 |
| 141 | The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS9124-TPS9124. | 0.8 | 11 |
| 142 | Design and implementation of a mobile system for lung cancer patient follow-up in China and initial report of the ongoing patient registry. Oncotarget, 2017, 8, 5487-5497. | 0.8 | 11 |
| 143 | Regulation of Î²-catenin-mediated esophageal cancer growth and invasion by miR-214. American Journal of Translational Research (discontinued), 2015, 7, 2316-25. | 0.0 | 11 |
| 144 | A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. American Journal of Translational Research (discontinued), 2021, 13, 743-756. | 0.0 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. <i>International Journal of Clinical Oncology</i> , 2022, 27, 695-706. | 1.0 | 11 |
| 146 | Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10. <i>Molecular Medicine Reports</i> , 2018, 17, 2153-2160. | 1.1 | 10 |
| 147 | A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2018, 9, 4718-4725. | 1.2 | 10 |
| 148 | The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging. <i>Oncology Reports</i> , 2019, 41, 2636-2646. | 1.2 | 10 |
| 149 | Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. <i>Lung Cancer</i> , 2019, 130, 18-24. | 0.9 | 10 |
| 150 | Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. <i>Cancer Medicine</i> , 2020, 9, 5134-5142. | 1.3 | 10 |
| 151 | Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. <i>Science China Life Sciences</i> , 2021, 64, 1590-1601. | 2.3 | 9 |
| 152 | Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. <i>BMC Cancer</i> , 2021, 21, 1033. | 1.1 | 9 |
| 153 | Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. <i>Oncotarget</i> , 2017, 8, 53675-53683. | 0.8 | 9 |
| 154 | Convergent alteration of lung tissue microbiota and tumor cells in lung cancer. <i>IScience</i> , 2022, 25, 103638. | 1.9 | 9 |
| 155 | Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 71-81. | 0.9 | 9 |
| 156 | The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells. <i>Current Therapeutic Research</i> , 2009, 70, 116-128. | 0.5 | 8 |
| 157 | Integrated discovery of FOXO1 DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer. <i>Molecular BioSystems</i> , 2017, 13, 330-337. | 2.9 | 8 |
| 158 | Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8565-8573. | 1.0 | 8 |
| 159 | Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. <i>Advances in Therapy</i> , 2021, 38, 2038-2053. | 1.3 | 8 |
| 160 | Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. <i>Annals of Translational Medicine</i> , 2021, 9, 950-950. | 0.7 | 8 |
| 161 | Meta-analysis for curative effect of lobectomy and segmentectomy on non-small cell lung cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 2599-604. | 1.3 | 8 |
| 162 | Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases. <i>Patient Preference and Adherence</i> , 2015, 9, 1165. | 0.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. <i>Journal of Molecular Medicine</i> , 2019, 97, 1657-1668. | 1.7 | 7 |
| 164 | Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 635-635. | 0.7 | 7 |
| 165 | Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 634920. | 1.3 | 7 |
| 166 | Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1959-1963. | 0.5 | 7 |
| 167 | Phase 3 study of first-line crizotinib vs pemetrexed+cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9058-9058. | 0.8 | 7 |
| 168 | A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21705-e21705. | 0.8 | 7 |
| 169 | A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436. | 1.3 | 7 |
| 170 | NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-L1 therapy. <i>Cancer Science</i> , 2021, , . | 1.7 | 7 |
| 171 | Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1192-1204. | 0.5 | 7 |
| 172 | Maintenance therapy for NSCLC: Consensus and controversy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2011, 23, 254-258. | 0.7 | 6 |
| 173 | Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. <i>Scientific Reports</i> , 2017, 7, 8483. | 1.6 | 6 |
| 174 | Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations. <i>Anti-Cancer Drugs</i> , 2019, 30, 873-878. | 0.7 | 6 |
| 175 | Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, e263-e266. | 0.5 | 6 |
| 176 | Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes. <i>European Journal of Surgical Oncology</i> , 2019, 45, 838-844. | 0.5 | 6 |
| 177 | AdvantIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9128-TPS9128. | 0.8 | 6 |
| 178 | International consensus on severe lung cancer—the first edition. <i>Translational Lung Cancer Research</i> , 2021, 10, 2633-2666. | 1.3 | 6 |
| 179 | CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8570-TPS8570. | 0.8 | 6 |
| 180 | XBP1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3D culture. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 700-707. | 0.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 163-e213. | 1.9 | 6 |
| 182 | The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. <i>Translational Lung Cancer Research</i> , 2022, 11, 213-223. | 1.3 | 6 |
| 183 | Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9096-9096. | 0.8 | 6 |
| 184 | An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-“small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 380-387. | 0.7 | 5 |
| 185 | Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC. <i>Cancer Medicine</i> , 2021, 10, 2286-2292. | 1.3 | 5 |
| 186 | Mini-“patient“ derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non-“small cell lung cancer. <i>Cell Biology International</i> , 2021, 45, 1887-1896. | 1.4 | 5 |
| 187 | Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-“Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 96-104. | 1.0 | 5 |
| 188 | <p>Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6543-6552. | 0.9 | 4 |
| 189 | Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing. <i>Annals of Translational Medicine</i> , 2021, 9, 140-140. | 0.7 | 4 |
| 190 | Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. <i>Translational Lung Cancer Research</i> , 2021, 10, 839-854. | 1.3 | 4 |
| 191 | Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring <i>MET exon 14</i> skipping alterations (<i>METex14</i>). <i>Cancer Research</i> , 2021, 81, CT158-CT158. | 0.4 | 4 |
| 192 | Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9554-9554. | 0.8 | 4 |
| 193 | The development of APS03118, a potent next-generation RET inhibitor for treating RET-inhibitor-resistant patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15107-e15107. | 0.8 | 4 |
| 194 | Isolation and characterization of ex vivo expanded mesenchymal stem cells obtained from a surgical patient. <i>Molecular Medicine Reports</i> , 2015, 11, 1777-1783. | 1.1 | 3 |
| 195 | A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174. | 2.0 | 3 |
| 196 | <p>Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1521-1538. | 1.0 | 3 |
| 197 | PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas. <i>Experimental Cell Research</i> , 2020, 395, 112187. | 1.2 | 3 |
| 198 | Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study,) Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 62 Tc 338-338. | 0.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. <i>Translational Lung Cancer Research</i> , 2021, 10, 3594-3607. | 1.3 | 3 |
| 200 | Development and validation of a deep learning model to assess tumor progression to immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20601-e20601. | 0.8 | 3 |
| 201 | FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy. <i>Frontiers in Oncology</i> , 2022, 12, 846744. | 1.3 | 3 |
| 202 | Modelled Economic Analysis for Dacomitinib—A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China. <i>Frontiers in Oncology</i> , 2021, 11, 564234. | 1.3 | 3 |
| 203 | Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. <i>Journal of Clinical Medicine</i> , 2022, 11, 2963. | 1.0 | 3 |
| 204 | KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8606-TPS8606. | 0.8 | 3 |
| 205 | Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIa) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial. <i>Cancer Research</i> , 2022, 82, CT012-CT012. | 0.4 | 3 |
| 206 | Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 4003. | 1.0 | 3 |
| 207 | Different roles of myofibroblasts in the tumorigenesis of nonsmall cell lung cancer. <i>Tumor Biology</i> , 2016, 37, 15525-15534. | 0.8 | 2 |
| 208 | Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 111, 43-50. | 0.9 | 2 |
| 209 | Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 803-806. | 1.3 | 2 |
| 210 | RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9102-9102. | 0.8 | 2 |
| 211 | Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9101-9101. | 0.8 | 2 |
| 212 | Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIa NSCLC patients with high VEGF expression. <i>Oncotarget</i> , 2017, 8, 79703-79711. | 0.8 | 2 |
| 213 | Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 323-330. | 1.3 | 2 |
| 214 | Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. <i>Future Oncology</i> , 2022, , . | 1.1 | 2 |
| 215 | Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC). <i>Cancer Research</i> , 2022, 82, LB512-LB512. | 0.4 | 2 |
| 216 | Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211124. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 580-582. | 0.5 | 1 |
| 218 | Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100142. | 0.6 | 1 |
| 219 | Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancers—Reply. <i>JAMA Oncology</i> , 2021, 7, 1580. | 3.4 | 1 |
| 220 | Molecular epidemiology of EGFR mutations in 7,953 non-small cell lung cancer of Chinese ethnicity. <i>Journal of Clinical Oncology</i> , 2014, 32, e19009-e19009. | 0.8 | 1 |
| 221 | A survival comparison study of Chinese patients with primary lung adenocarcinoma harboring ALK rearrangements with crizotinib treatment detected by FISH, IHC, and RT-PCR. <i>Journal of Clinical Oncology</i> , 2015, 33, e19135-e19135. | 0.8 | 1 |
| 222 | Differential crizotinib efficacy among ROS1 fusion partners in ROS1-positive non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 9067-9067. | 0.8 | 1 |
| 223 | Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV). <i>Journal of Clinical Oncology</i> , 2017, 35, 10090-10090. | 0.8 | 1 |
| 224 | Mutation profiling and treatment choosing of Chinese ROS1 positive advanced lung cancer patients. <i>Journal of Clinical Oncology</i> , 2018, 36, e21102-e21102. | 0.8 | 1 |
| 225 | A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. <i>Future Oncology</i> , 2021, 17, 4827-4835. | 1.1 | 1 |
| 226 | Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations. <i>Lung Cancer</i> , 2021, 162, 207-209. | 0.9 | 1 |
| 227 | Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists. <i>Annals of Translational Medicine</i> , 2022, 10, 41-41. | 0.7 | 1 |
| 228 | Abstract 5363: The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor. <i>Cancer Research</i> , 2022, 82, 5363-5363. | 0.4 | 1 |
| 229 | Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. <i>Cancer Research</i> , 2022, 82, CT505-CT505. | 0.4 | 1 |
| 230 | The relationship between the pathological changes and response rate (RR) in non-small cell lung cancer treated by neoadjuvant chemotherapy with mitomycin (MMC), vindesine (VDS) and cisplatin (DDP) combination. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2000, 12, 220-223. | 0.7 | 0 |
| 231 | Perioperative chemotherapy of stage III N2 non-small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 185-189. | 0.1 | 0 |
| 232 | Immuno-Oncology in China. <i>Oncologist</i> , 2019, 24, S1-S2. | 1.9 | 0 |
| 233 | Adverse Effects of Combined Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, e182-e183. | 0.5 | 0 |
| 234 | Chinese advanced fusion-dependent lung cancer patients: Molecular spectrum and treatment options using next generation sequencing—A multicenter study (Yangtze River Delta Lung Cancer Cooperation) Tj ETQq0008 rgBT (Overlock 1 | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Abstract CT255: Canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer: CANOPY-A trial. , 2021, , . | | 0 |
| 236 | Sirtuin expression is downregulated in non-small cell lung cancer. FASEB Journal, 2010, 24, 567.3. | 0.2 | 0 |
| 237 | Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392).. Journal of Clinical Oncology, 2012, 30, 7091-7091. | 0.8 | 0 |
| 238 | Effect of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA unresectable non-small cell lung cancer (CTONG 1101, NCT01297101) on disease-free survival: A single arm, multi-center, phase II study.. Journal of Clinical Oncology, 2015, 33, e18519-e18519. | 0.8 | 0 |
| 239 | Genome-wide screen of DNA methylation study in stage IIIa (N2) EGFR 19 deletion adenocarcinoma with erlotinib treatment.. Journal of Clinical Oncology, 2016, 34, e20067-e20067. | 0.8 | 0 |
| 240 | Association of circulating tumor DNA clearance during treatment with improved progression-free survival in advanced non-small cell lung cancer patients.. Journal of Clinical Oncology, 2017, 35, 11528-11528. | 0.8 | 0 |
| 241 | Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.. Journal of Clinical Oncology, 2019, 37, 9095-9095. | 0.8 | 0 |
| 242 | Role of WNT1-inducible-signaling pathway protein 1 in etoposide resistance in lung adenocarcinoma A549 cells. International Journal of Clinical and Experimental Medicine, 2015, 8, 14962-8. | 1.3 | 0 |
| 243 | 366...A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC. , 2020, , . | | 0 |
| 244 | Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade. Journal of Thoracic Oncology, 2022, 17, 341-344. | 0.5 | 0 |
| 245 | Abstract 5537: MGA mutation status affect tumor immunomicroenvironment and predict the effect of immune check point inhibitor: From NSCLC to pan-cancers analysis. Cancer Research, 2022, 82, 5537-5537. | 0.4 | 0 |
| 246 | Abstract CT552: RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 years. Cancer Research, 2022, 82, CT552-CT552. | 0.4 | 0 |